HOGAN & HARTSON

L.L.P.

3060 °04 FEB 12 P251

COLUMBIA SQUARE
555 THIRTEENTH STREET, NW
WASHINGTON, DC 20004-1109
TEL (202) 637-5600
FAX (202) 637-5910

WWW.HHLAW.COM

DAVID M. FOX
PARTNER
(202) 637-5678
DMFOX@HHLAW. COM

February 11, 2003

VIA HAND DELIVERY

Dockets Management Branch (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD 20852

> Re: Docket Number 2003P-0321/CP1 Notice of Name Change

Dear Sir or Madam:

On July 16, 2003, we submitted the above-referenced citizen petition on behalf of Ribapharm Inc. (Ribapharm) and ICN Pharmaceuticals, Inc. (ICN). As of year-end 2003, Ribapharm became a wholly-owned subsidiary of ICN, and ICN changed its corporate name to Valeant Pharmaceuticals International.

In light of this change, please note that the citizen petition and all subsequent filings should be regarded as pending under the corporate name "Valeant Pharmaceuticals International," and all subsequent correspondence regarding the above-captioned matter should utilize the corporate name "Valeant Pharmaceuticals International" in place of ICN and Ribapharm.

Please let us know if you have any questions regarding this notice of name change for the petitioner.

Sincerely,

David M. Fox

Let 3

2003P-0321